Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | OR502 |
Synonyms | |
Therapy Description |
OR502 is an anti-LILRB2 antibody, which interferes with binding of LILRB2 to HLA class I molecules and potentially enhances antitumor immune response (Journal for ImmunoTherapy of Cancer 2023;11). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
OR502 | OR 502|OR-502 | LILRB2 Antibody 11 | OR502 is an anti-LILRB2 antibody, which interferes with binding of LILRB2 to HLA class I molecules and potentially enhances antitumor immune response (Journal for ImmunoTherapy of Cancer 2023;11). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|